EUVIMEDEUVIMED entdecken
Crossref

Pyrotinib Plus Trastuzumab and Docetaxel with Different Antidiarrheal Strategies in Patients with HER2-Positive Recurrent or Metastatic Breast Cancer (PHAENNA): A Multicenter, Phase 1 Trial

Wei Ren, Xiuping Lai, Guiying Bai, Yanqiong Liu, Hongtao Li, Huan Zhou, Shouman Wang, Qun Qin, Wei Li, Cuizhi Geng, Mingxia Wang, Xinshuai Wang und 13 weitere

Cancer Research and Treatment · 28.07.2026

DOI: 10.4143/crt.2026.0400 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Research and Treatment, online erschienen am 28.07.2026. Verfasst von Wei Ren und 24 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Department of phase I Clinical Trial Centre, Breast Tumor Cen….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

Antidiarrheal strategyBreast neoplasmsHER-targeted tyrosine kinase inhibitorPyrotinib

Autor:innen und Institutionen

  • Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Department of phase I Clinical Trial Centre, Breast Tumor Centre, Medical Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen Univ…
  • Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin, China.
  • State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin, China.
  • The First Affiliated Hospital of Bengbu Medical University, Bengbu, China.
  • Xiangya Hospital of Central South University, Changsha, China.
  • The First Bethune Hospital of Jilin University, Changchun, China.

Zitieren

APA

Ren, W., Lai, X., Bai, G., Liu, Y., Li, H., Zhou, H., Wang, S., Qin, Q., Li, W., Geng, C., Wang, M., Wang, X., Cao, Y., Yu, Z., Du, C., Zhao, W., Wu, S., Cui, Y., Liu, P., …, & Yao, H. (2026). Pyrotinib Plus Trastuzumab and Docetaxel with Different Antidiarrheal Strategies in Patients with HER2-Positive Recurrent or Metastatic Breast Cancer (PHAENNA): A Multicenter, Phase 1 Trial. Cancer Research and Treatment. https://doi.org/10.4143/crt.2026.0400

Vancouver

Ren W, Lai X, Bai G, Liu Y, Li H, Zhou H, et al. Pyrotinib Plus Trastuzumab and Docetaxel with Different Antidiarrheal Strategies in Patients with HER2-Positive Recurrent or Metastatic Breast Cancer (PHAENNA): A Multicenter, Phase 1 Trial. Cancer Research and Treatment. 2026. doi:10.4143/crt.2026.0400

BibTeX
@article{Ren2026,
  author = {Ren, Wei and Lai, Xiuping and Bai, Guiying and Liu, Yanqiong and Li, Hongtao and Zhou, Huan and Wang, Shouman and Qin, Qun and Li, Wei and Geng, Cuizhi and Wang, Mingxia and Wang, Xinshuai and Cao, Yu and Yu, Zhuang and Du, Caiwen and Zhao, Wei and Wu, Shikai and Cui, Yimin and Liu, Pan and Zhao, Kaijing and Lin, Jiaman and Zhu, Xiaoyu and Yao, Yandan and Shi, Yehui and Yao, Herui},
  title = {Pyrotinib Plus Trastuzumab and Docetaxel with Different Antidiarrheal Strategies in Patients with HER2-Positive Recurrent or Metastatic Breast Cancer (PHAENNA): A Multicenter, Phase 1 Trial},
  journal = {Cancer Research and Treatment},
  year = {2026},
  doi = {10.4143/crt.2026.0400}
}
Kostenlos starten →